| Citation: |
DUAN Xiaoyang, SHI Jian. Research Status and Progress on Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma in Hebei Province[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 103-109. DOI: 10.3971/j.issn.1000-8578.2025.24.0856
|
Esophageal squamous cell carcinoma (ESCC) is one of the most prevalent gastrointestinal cancers in Hebei province. Most patients are diagnosed at an advanced stage due to untypical early symptoms, making surgical treatment often unfeasible. As a result, most of them are treated with comprehensive medical treatment, which tends to have limited effectiveness and poor prognosis. However, the recent introduction of immunotherapy has considerably advanced treatment options for patients with advanced ESCC, notably improving their prognosis. Uncertainties regarding immune resistance, the selection of predictive indicators of efficacy, the identification of dominant population, and the choice of combined treatment strategies are still evident. Therefore, based on the high incidence and poor prognosis of ESCC in Hebei Province, this article will briefly review the research progress in the treatment of advanced ESCC, aiming to provide guidance for treatment strategies for advanced esophageal cancer.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. doi: 10.3322/caac.21834
|
| [2] |
谷变利, 马丽霞, 石林林, 等. 食管癌流行病学研究现状及展望[J]. 食管疾病, 2024, 6(2): 148-151. [Gu BL, Ma LX, Shi LL, et al. Advances and Prospects in Epidemiological Research on Esophageal Cancer[J]. Shi Guan Ji Bing, 2024, 6(2): 148-151.]
Gu BL, Ma LX, Shi LL, et al. Advances and Prospects in Epidemiological Research on Esophageal Cancer[J]. Shi Guan Ji Bing, 2024, 6(2): 148-151.
|
| [3] |
陈万青, 张思维, 陈志峰. 中国食管癌胃癌高发区贲门癌流行趋势分析[J]. 中国肿瘤, 2008, 17(12): 998-1000. [Chen WQ, Zhang SW, Chen ZF. An epidemiologic trend analysis on cardiac cancer in high incidence areas of esophageal cancer and gastric cancer in China[J]. Zhongguo Zhong Liu, 2008, 17(12): 998-1000.]
Chen WQ, Zhang SW, Chen ZF. An epidemiologic trend analysis on cardiac cancer in high incidence areas of esophageal cancer and gastric cancer in China[J]. Zhongguo Zhong Liu, 2008, 17(12): 998-1000.
|
| [4] |
陈瑜, 蔡文科, 罗小迪, 等. 食管癌地域性差异研究进展[J]. 肿瘤防治研究, 2024, 51(6): 488-494. [Chen Y, Cai WK, Luo XD, et al. Progress of Research on Regional Differences in Esophageal Cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2024, 51(6): 488-494.] doi: 10.3971/j.issn.1000-8578.2024.23.1227
Chen Y, Cai WK, Luo XD, et al. Progress of Research on Regional Differences in Esophageal Cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2024, 51(6): 488-494. doi: 10.3971/j.issn.1000-8578.2024.23.1227
|
| [5] |
单保恩, 贺宇彤. 2023河北省肿瘤登记年报[M]. 北京: 清华大学出版社, 2023. [Shan BN, He YT. 2023 Hebei Cancer Registry Annual Report[M]. Beijing: Tsinghua University Press, 2023.]
Shan BN, He YT. 2023 Hebei Cancer Registry Annual Report[M]. Beijing: Tsinghua University Press, 2023.
|
| [6] |
李道娟, 刘言玉, 贺宇彤, 等. 2018年河北省肿瘤登记地区上消化道癌流行现状及1988-2018年高发区流行特征变化趋势[J]. 中国肿瘤, 2023, 32(6): 407-413. [Li DJ, Liu YY, He YT, et al. Incidence and Mortality of Upper Gastrointestinal Cancer in Cancer Registration Areas of Hebei Province in 2018 and the Trends in High Risk Areas from 1988 to 2018[J]. Zhongguo Zhong Liu, 2023, 32(6): 407-413.]
Li DJ, Liu YY, He YT, et al. Incidence and Mortality of Upper Gastrointestinal Cancer in Cancer Registration Areas of Hebei Province in 2018 and the Trends in High Risk Areas from 1988 to 2018[J]. Zhongguo Zhong Liu, 2023, 32(6): 407-413.
|
| [7] |
宋国慧, 李东方. 河北省磁县食管癌早诊早治实践与思考[J]. 中国肿瘤, 2015, 24(1): 39-41. [Song GH, Li DF. Practice of Early Diagnosis and Treatment for Esophageal Cancer in Cixian, Heibei Province[J]. Zhongguo Zhong Liu, 2015, 24(1): 39-41.] doi: 10.11735/j.issn.1004-0242.2015.01.A008
Song GH, Li DF. Practice of Early Diagnosis and Treatment for Esophageal Cancer in Cixian, Heibei Province[J]. Zhongguo Zhong Liu, 2015, 24(1): 39-41. doi: 10.11735/j.issn.1004-0242.2015.01.A008
|
| [8] |
刘言玉, 赵连梅, 贺宇彤, 等. 河北省上消化道恶性肿瘤病因研究及预防[J]. 中国肿瘤, 2023, 32(6): 431-435. [Liu YY, Zhao LM, He YT, et al. Etiology and prevention of upper gastrointestinal cancer in Hebei Province[J]. Zhongguo Zhong Liu, 2023, 32(6): 431-435.]
Liu YY, Zhao LM, He YT, et al. Etiology and prevention of upper gastrointestinal cancer in Hebei Province[J]. Zhongguo Zhong Liu, 2023, 32(6): 431-435.
|
| [9] |
Weidenbaum C, Gibson MK. Approach to Localized Squamous Cell Cancer of the Esophagus[J]. Curr Treat Options Oncol, 2022, 23(10): 1370-1387. doi: 10.1007/s11864-022-01003-w
|
| [10] |
Wang DR, Wu XL, Sun YL. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response[J]. Signal Transduct Target Ther, 2022, 7(1): 331. doi: 10.1038/s41392-022-01136-2
|
| [11] |
Tanaka T, Nakamura J, Noshiro H. Promising immunotherapies for esophageal cancer[J]. Expert Opin Biol Ther, 2017, 17(6): 723-733. doi: 10.1080/14712598.2017.1315404
|
| [12] |
Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer[J]. Am J Cancer Res, 2020, 10(3): 727-742.
|
| [13] |
De Silva P, Aiello M, Gu-Trantien C, et al. Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?[J]. Int J Cancer, 2021, 149(1): 31-41. doi: 10.1002/ijc.33415
|
| [14] |
马兹芬, 许维恒, 金煜翔, 等. 食管癌的靶向治疗与免疫治疗研究进展[J]. 药学实践与服务, 2024, 42(6): 231-237. [Ma ZF, Xu WH, Jin YX, et al. Research progress on targeted therapy and immunotherapy for esophageal cancer[J]. Yao Xue Shi Jian Yu Fu Wu, 2024, 42(6): 231-237.]
Ma ZF, Xu WH, Jin YX, et al. Research progress on targeted therapy and immunotherapy for esophageal cancer[J]. Yao Xue Shi Jian Yu Fu Wu, 2024, 42(6): 231-237.
|
| [15] |
Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302): 759-771. doi: 10.1016/S0140-6736(21)01234-4
|
| [16] |
Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma[J]. N Engl J Med, 2022, 386: 449-462. doi: 10.1056/NEJMoa2111380
|
| [17] |
Luo H, Lu J, Bai Y, et al. Effect of Camrelizumab vs. Placebo Added to Chemotherapy on Survival and Progression Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial[J]. JAMA, 2021, 326(10): 916-925. doi: 10.1001/jama.2021.12836
|
| [18] |
Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy intreatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial [J]. Cancer Cell, 2022, 40(3): 277-288. e3.
|
| [19] |
Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial[J]. BMJ, 2022, 377: e068714.
|
| [20] |
Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2023, 24(5): 483-495. doi: 10.1016/S1470-2045(23)00108-0
|
| [21] |
Song Y, Zhang B, Xin D, et al. First-line serplulimab or placebo plus chemotherapy in PD-L1 positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial[J]. Nat Med, 2023, 29(2): 473-482. doi: 10.1038/s41591-022-02179-2
|
| [22] |
Li J, Chen Z, Bai Y, et al. 0-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)[J]. Ann Oncol, 2023, 34(Suppl 1): S181-S182.
|
| [23] |
Sun JM, Lin CY, Rojas C, et al. 1534P First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (mESCC) : Safety run in results from the phase III LEAP-014 study[J]. Ann Oncol, 2023 (Suppl 2), 34: S863.
|
| [24] |
Xu M, Pu Y, Jiang Y, et al. 1542P Updated results of a phase II clinical trial: Paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced oesophageal cancer[J]. Ann Oncol, 2023 (Suppl 2), 34: S866.
|
| [25] |
Wang JS, Li N, Guo YZ, et al. TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase Ⅱ trial[J]. J Clin Oncol, 2023, 41(Suppl 16): e16034.
|
| [26] |
Hsu CH. SKYSCRAPER-08: A phase Ⅲ, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC)[R]. San Francisco: ASCO GI, 2024.
|
| [27] |
Sun M, Spigel DR, Lee YJ, et al. 1533P Advantig-105: Phase Ib dose expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (CT) in patients (pts) with metastatic oesophageal squamous cell carcinoma (ESCC) and oesophageal adenocarcinoma (EAC)[J]. Ann Oncol, 2023 (Suppl 2), 34: S862-S863.
|
| [28] |
Yamamoto S, Muro K, Nishino K, et al. 1532P Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy[J]. Ann Oncol, 2023 (Suppl 2), 34: S861-S862.
|
| [29] |
Huang J, Liu Y, Wu T, et al. A phase 2 study of HLX07 as monotherapy or combination therapy in patients with locally advanced, unresectable, or metastatic esophageal squamous cell carcinoma[J]. J Clin Oncol, 2023, 41(Suppl 16): 4029.
|
| [30] |
Hong YG, Meng X, Yang X, et al. 1531P Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC) : A single arm, multicenter, open label phase Ⅱ clinical trial[J]. Ann Oncol, 2023 (Suppl 2), 34: S861.
|
| [31] |
Li N, Wu T, Hong YG, et al. A multi-center, single-arm, phase Ⅱ study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma[J]. BMC Med, 2022, 20(1): 472. doi: 10.1186/s12916-022-02649-x
|
| [32] |
Kojima T, Shah MA, Muro K, et al. Randomized Phase Ⅲ KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer[J]. J Clin Oncol, 2020, 38(35): 4138-4148. doi: 10.1200/JCO.20.01888
|
| [33] |
Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase3 trial[J]. Lancet Oncol, 2019, 20(11): 1506-1517. doi: 10.1016/S1470-2045(19)30626-6
|
| [34] |
Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): amulticentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 832-842. doi: 10.1016/S1470-2045(20)30110-8
|
| [35] |
Shen L, Kato K, Kim SB, et al. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase Ⅲ Study[J]. J Clin Oncol, 2022, 40(26): 3065-3076. doi: 10.1200/JCO.21.01926
|
| [36] |
Zhuo N, Liu C, Zhang Q, et al. Characteristics and prognosis of acquired resistance to immune checkpoint inhibitors in gastrointestinal cancer[J]. JAMA Netw Open, 2022, 5(3): e224637. doi: 10.1001/jamanetworkopen.2022.4637
|
| [37] |
Meng XR, Wang JS, Xia J, et al. Camrelizumab plus apatinib after progression on immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma (CAP 02 Re-challenge) : A single-arm, multicenter, phase Ⅱ trial[J]. J Clin Oncol, 2024, 42(Suppl 3): 364.
|
| [38] |
Huang J, Liu J, Hong Y, et al. P-162 Preliminary results of the feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): A retrospective exploratory study[J]. Ann Oncol, 2023, 34(Suppl 1): S73.
|
| [39] |
Wang F, Lin CY, Sun JM, et al. 1020MO AdvanTIG-203: Phase Ⅱ randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity[J]. Ann Oncol, 2023, 34(Suppl 2): S621.
|
| [40] |
Zheng J, Huang B, Xiao L, et al. Treatment-and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials[J]. Front Oncol, 2022, 12: 821626. doi: 10.3389/fonc.2022.821626
|
| [41] |
《中国消化道肿瘤免疫治疗不良反应专家共识(2023年版)》编写组. 中国消化道肿瘤免疫治疗不良反应专家共识(2023年版)[J]. 肿瘤综合治疗电子杂志, 2023, 9(2): 26-60. [Writing group of Consensus on immune-related adverse events of gastrointestinal tumor in China (2023 edition). Consensus on immune-related adverse events of gastrointestinal tumor in China (2023 edition)[J]. Zhong Liu Zong He Zhi Liao Dian Zi Za Zhi, 2019, 9(2): 26-60.]
Writing group of Consensus on immune-related adverse events of gastrointestinal tumor in China (2023 edition). Consensus on immune-related adverse events of gastrointestinal tumor in China (2023 edition)[J]. Zhong Liu Zong He Zhi Liao Dian Zi Za Zhi, 2019, 9(2): 26-60.
|
Tables(2)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: